Mundipharma's Pelmeg, or pegfilgrastim, has been approved by European regulators to reduce the duration of neutropenia and the incidence of febrile neutropenia in adult patients whose malignancies were treated with cytotoxic chemotherapy. The drug is a biosimilar to Amgen's Neulasta.
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.